Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUMELEP trial of durvalumab + tremelimumab around curative percutaneous ablation for hepatocellular carcinoma
2024-515768-30-01Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Mar 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab and tremelimumab in hepatocellular carcinoma (HCC), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: One-year local recurrence-free survival. Planned start Mar 2024; status: authorised.
02
Drugs
durvalumabtremelimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2024-515768-30-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515768-30-01.